| Over a week ago | ||||
JPMorgan analyst David… JPMorgan analyst David Adlington raised the firm's price target on Coloplast to DKK 800 from DKK 798 and keeps a Neutral rating on the shares. | ||||
Barclays analyst Hassan… Barclays analyst Hassan Al-Wakeel lowered the firm's price target on Coloplast to DKK 815 from DKK 835 and keeps an Underweight rating on the shares. | ||||
| Over a month ago | ||||
Barclays analyst Hassan… Barclays analyst Hassan Al-Wakeel raised the firm's price target on Coloplast to DKK 835 from DKK 780 and keeps an Underweight rating on the shares. | ||||
Credit Suisse analyst… Credit Suisse analyst Christoph Gretler lowered the firm's price target on Coloplast to DKK 1,045 from DKK 1,100 and keeps an Outperform rating on the shares. | ||||
UBS analyst Graham Doyle… UBS analyst Graham Doyle lowered the firm's price target on Coloplast to DKK 840 from DKK 878 and keeps a Neutral rating on the shares. | ||||
| Over a quarter ago | ||||
Morgan Stanley analyst… Morgan Stanley analyst Robert Davies initiated coverage of Coloplast with an Overweight rating and DKK 978 price target. The EU Medtech group "looks attractive after the 2022 reset," said Davies as he initiated coverage of the group, citing its defensive characteristics and that fact that the stocks are "already an outlier among defensive industry groups." | ||||
Jefferies analyst James… Jefferies analyst James Vane-Tempest downgraded Coloplast to Hold from Buy with a price target of DKK 880, down from DKK 1,150. The analyst sees potential downside from inflation and the company's exposure to China. | ||||
Credit Suisse analyst… Credit Suisse analyst Christoph Gretler raised the firm's price target on Coloplast to DKK 1,100 from DKK 1,080 and keeps an Outperform rating on the shares. | ||||
UBS analyst Graham Doyle… UBS analyst Graham Doyle raised the firm's price target on Coloplast to DKK 878 from DKK 857 and keeps a Neutral rating on the shares. | ||||
JPMorgan analyst David… JPMorgan analyst David Adlington lowered the firm's price target on Coloplast to DKK 798 from DKK 980 and keeps a Neutral rating on the shares. | ||||
